Verismo is ramping up its 2 Phase 1s targeting solid tumors and B-Cell non-Hodgkin lymphomas, selecting Cryoport for its cold chain.
The Australian biotech company is hoping to tackle aGvHD in Europe, which appears to have twice as many cases as the USA.
The therapy has been approved in the USA since 2024, and it'll soon be available down under as well, potentially reimbursed by Australia's pharma subsidy program.
Following their successful Phase 1, they've received clearance to begin Phase 2, where they'll assess whether it can reduce transfusion needs by calming the immune attack on bone marrow.
A phase 2 trial found that adding a lab-expanded stem cell product made from multiple pooled cord blood donors to a single cord blood transplant may broaden access to transplants for leukemia and myelodysplastic syndrome patients by speeding early immune recovery while avoiding severe transplant…
South Korea’s KDCA has begun distributing the nation’s first clinical-grade induced pluripotent stem cell lines, a move expected to cut costs and speed development of artificial blood and other cell-based therapies.
HexemBio plans to advance its platform designed to rejuvenate aging blood stem cells, with an initial focus on improving bone marrow transplant outcomes in blood cancers.
Zemcelpro (dorocubicel) is designed to support blood and immune system recovery after myeloablative conditioning in patients with hematologic diseases.
The partnership aims to streamline production and quality testing of gene-edited hematopoietic stem cell therapies for HIV and rare diseases.
The new grants will support diverse early-stage research projects, aiming to advance regenerative medicine tools and future therapies.
The Australian biotech company is preparing for trials and commercialization of its stem cell therapy platform for Crohn's disease, StemSmart.
It's interesting to consider, much like with umbilical cords, how often are we incinerating life-saving stem cells?
The new facility at CEPM positions Cell BioEngines to accelerate research and forge partnerships advancing innovative cell therapies.
A significant milestone for the stem cell industry, likely paving the way for future stem cell based therapies.
New funds aim to advance Garuda’s pipeline toward clinical trials, expand manufacturing capabilities, and support operational growth.